If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Digital Health Announces Stallergenes Greer iPUMP Launch

    Quick Contact
    • Aptar Pharma
    Aptar Digital Health Announces Stallergenes Greer iPUMP Launch
    Health, Pharmaceuticals, Drug Delivery Devices, Active, Smart Packaging
    • iPUMP® is the first connected allergy management assistant, launched recently by Stallergenes Greer in France

    Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, has developed iPUMP®, the first connected allergy assistant which was recently launched in France by Stallergenes Greer, a global healthcare company specialising in Allergen Immunotherapy Treatment (AIT).

    Designed for patients treated with Stallergenes Greer’s liquid sublingual AITs, the availability of iPUMP® followed a pilot phase conducted by Stallergenes Greer during which 92% of patients systematically used iPUMP® while taking their treatment. With the launch of this technological innovation, both Aptar Digital Health and Stallergenes Greer are responding to two of the major challenges in the day-to-day management of AIT treatments non-adherence and premature discontinuation of treatment.

    “With iPUMP®, the patient experience in the management of AIT is simpler. Thanks to multiple functionalities, patients can closely monitor their adherence, thus optimizing their treatment outcomes,” said Sai Shankar, President of Aptar Digital Health. “This collaboration with a leading company in the field of AIT illustrates Aptar Digital Health’s ability to deliver innovative, effective, and easy-to-use solutions to improve the patient’s experience with their therapy.”

    iPUMP® features a connected pressure sensor that converts the force exerted into an audible signal as soon as the threshold is reached, which confirms that the treatment has been taken. An integrated timer marks the end of the daily dose as prescribed, and a visual cue confirms if the daily dose has been taken.

    iPUMP® is connected to a mobile application of the same name, which gives direct access to the protocol prescribed by the doctor. iPUMP® helps patients improve compliance with their treatment to optimize its efficacy while offering a function for tracking intake history for precise medication monitoring.

    During the pilot phase, 74% of patients under 15 years of age adopted iPUMP® to improve their compliance, and almost two-thirds of participants perceived the solution as a real support in taking their liquid sublingual AIT.

    This development and launch of iPUMP® marks an important milestone in a longstanding partnership between Aptar Digital Health and Stallergenes Greer. Based on their proprietary software platform, iPUMP® confirms Aptar Digital Health’s status as a major player in digital health innovation, as well as its capabilities to develop hardware and software solutions to the benefit of both the patient and the medical community.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Brand Launch
    • English
    • Modified 07 Dec 2023
    • Hits 147
    Conzept International
    Quadpack
    SR Packaging